Abstract
Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Current Molecular Medicine
Title: Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Volume: 11 Issue: 9
Author(s): M. Mariani, S. Shahabi, S. Sieber, G. Scambia and C. Ferlini
Affiliation:
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Abstract: Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Export Options
About this article
Cite this article as:
Mariani M., Shahabi S., Sieber S., Scambia G. and Ferlini C., Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?, Current Molecular Medicine 2011; 11 (9) . https://dx.doi.org/10.2174/156652411798062368
DOI https://dx.doi.org/10.2174/156652411798062368 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Microbial / Enzymatic Synthesis of Chiral Intermediates for Pharmaceuticals: Case Studies from BMS
Current Organic Chemistry Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Development, Potential Anticancer Activity and the Receptor Profile of Different Functionalized 1,3,5-Triazine Derivatives
Mini-Reviews in Medicinal Chemistry Recent Advances in Intervention in Markovian Regulatory Networks
Current Genomics Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer
Current Pharmaceutical Design Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results
Reviews on Recent Clinical Trials USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer
Current Cancer Drug Targets ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Potential of Modulating Wnt Signaling Pathway Toward the Development of Bone Anabolic Agent
Current Molecular Pharmacology Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design Mapping Myeloperoxidase to Identify its Promiscuity Properties Using Docking and Molecular Dynamics Simulations
Current Pharmaceutical Design